– Inflexion, a leading European mid-market private equity firm, has closed Inflexion Continuation Fund I at £2.3 billion — the largest multi-asset continuation fund raised in Europe to date.
– The Fund allows four portfolio companies to pursue ambitious growth plans, especially through M&A, while providing significant liquidity to existing investors and an opportunity for re-investment.
– The Fund includes global leaders and category champions across resilient sectors, aligned with strong market tailwinds.
– Inflexion will continue applying its proven value creation strategy, including international expansion, organic growth initiatives, transformational M&A (a key focus for capital deployment)
– Companies in the Continuation Fund: Aspen Pumps Group, Rosemont Pharmaceuticals, Ocorian, and CNX Therapeutics | B Corp™ Certified.
– The transaction delivers 3.4x realised return, 28% IRR, and £1.5 billion in net proceeds to existing Inflexion investors.
– Inflexion’s overall track record includes 71 exits, 3.4x average realised return, and 33% IRR since inception.
– The Fund was oversubscribed and underwritten by Carlyle AlpInvest, HarbourVest Partners, Lexington Partners, plus contributions from other existing and new investors.
– Florencia Kassai, Managing Partner emphasized opportunity to accelerate growth of portfolio companies through M&A
– George Collier, COO highlighted the strategic importance of the fund and continued investor collaboration
